Cargando…
Immunotherapy in small cell lung cancer: one step at a time: a narrative review
Chemotherapy with or without radiotherapy has been the standard of care for many years for patients with small cell lung cancer (SCLC). Despite exceptionally high responses (up to 80%) with chemotherapy, the majority of patients relapse rapidly within weeks to months after treatment completion. Ther...
Autores principales: | Dumoulin, Daphne W., Dingemans, Anne-Marie C., Aerts, Joachim G. J. V., Remon, Jordi, De Ruysscher, Dirk K. M., Hendriks, Lizza E. L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264327/ https://www.ncbi.nlm.nih.gov/pubmed/34295691 http://dx.doi.org/10.21037/tlcr-20-630 |
Ejemplares similares
-
Is there any opportunity for immune checkpoint inhibitor therapy in non-small cell lung cancer patients with brain metastases?
por: Hendriks, Lizza E. L., et al.
Publicado: (2021) -
Immunotherapy in other thoracic malignancies and uncommon populations
por: Remon, Jordi, et al.
Publicado: (2021) -
Immunotherapy in malignant pleural mesothelioma: a review of literature data
por: Menis, Jessica, et al.
Publicado: (2021) -
Narrative review of immunotherapy in thymic malignancies
por: Benitez, Jose Carlos, et al.
Publicado: (2021) -
Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer
por: Duchemann, Boris, et al.
Publicado: (2021)